Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
25 Maio 2023 - 4:37PM
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the
global leader in blood volume measurement technology, today
announced the closing of its previously announced underwritten
public offering of 410,260 shares of its common stock at a public
offering price of $9.75 per share. Gross proceeds from the offering
are approximately $4.0 million before deducting underwriting
discounts, commissions, and estimated offering expenses.
Maxim Group LLC acted as the sole book-running
manager and Joseph Gunnar & Co., LLC acted as co-manager for
the offering.
Daxor intends to use the net proceeds from the
offering for working capital and other general corporate purposes,
including to develop our products, fund capital expenditures, make
investments in or acquisitions of other businesses, solutions or
technologies or repay a portion of our outstanding borrowings.
Daxor has granted the underwriters a 45-day
option to purchase up to an additional 61,539 shares of common
stock.
A shelf registration statement on Form N-2 (File
Nos. 333-255212 and 811-22684) relating to the securities being
offered was filed with the U.S. Securities and Exchange Commission
(the “SEC”) on April 13, 2021, and became effective on July 16,
2021. The shares may be offered only by means of a prospectus. A
final prospectus supplement describing the terms of the public
offering has been filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus relating to the public offering may
also be obtained by contacting Maxim Group LLC, at 300 Park Avenue,
16th Floor, New York, NY 10022, Attention: Prospectus Department,
or by telephone at (212) 895-3745 or by email at
syndicate@maximgrp.com. Before you invest, you should read the
preliminary prospectus supplement and accompanying prospectus,
together with the information incorporated therein, for more
complete information about Daxor and the offering.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About
Daxor:
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 60,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing multicenter trials in
the areas of COVID-19 and heart failure treatment with support from
the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor’s
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements:
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024